Venetoclax
Other Antineoplastic Agents
Sold as Venclyxto · VENCLEXTA
- Drug class
- Other Antineoplastic Agents
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 13
Overview
Venetoclax is an active pharmaceutical ingredient in the Other Antineoplastic Agents group (L01XX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 8 | May 22, 2026 |
| EU European Union | EMA | 1 | October 24, 2025 |
| CA Canada | Health Canada | 4 | May 22, 2026 |
GBUnited Kingdom· MHRA
8 products
Uses
1) • in combination with ibrutinib Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. Venclyxto monotherapy is indicated for the treatment of CLL: • in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or • in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.
Venclyxto in combination with a hypomethylating agent or low-dose cytarabine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
How to take
EUEuropean Union· EMA
1 product
Uses
1). Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. Venclyxto monotherapy is indicated for the treatment of CLL: • in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or • in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.
Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. 3
How to take
CACanada· Health Canada
4 products
4 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Venetoclax. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 259. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB410420036 · revised May 22, 2026
- [2]European Medicines Agency · EMEA/H/C/004106 · revised October 24, 2025
- [3]Health Canada (DPD) · 02458039 · revised May 22, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.